April 13 Quick Takes: AZ’s Phase III of Tagrisso unblinded early; plus BeiGene’s tislelizumab and Fennec’s Pedmark

‘Overwhelming efficacy’ for Tagrisso in NSCLC
AstraZeneca plc (LSE:AZN; NYSE:AZN) said an IDMC recommended the Phase III ADAURA trial of Tagrisso osimertinib

Read the full 218 word article

How to gain access

Continue reading with a
two-week free trial.